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&Aminolevulinate dehydratase (ALAD) is the second enzyme in the heme biosynthesis pathway. ALAD is a zinc metalloenzyme, and its inhibition by
lead substitution for zinc is one of the most sensitive indicators of blood-lead accumulation, a measure of recent lead exposure. Stoichiometry calcu-
lations indicate that a significant portion of blood lead is stored in ALAD. Human ALAD exhibits a charge polymorphism, with about 20% of
Caucasians expressing the rarer ALAD2 allele. Human ALAD1 and ALAD2 cDNAs and the 16-kb ALAD gene have been cloned and sequenced. A
simple polymerase chain reaction test has been established and validated for determining ALAD genotypes. Two population studies have indicated
that lead-exposed individuals with the ALAD allele have blood-lead levels about 10 pg/dl greater than similarly exposed individuals carrying only the
ALAD1 allele. Ongoing work is directed toward determining the biochemistry underlying the allele-specific accumulation of blood lead, and toward
determining the contribution of human ALAD genotype to lead accumulation in other tissues in transgenic mouse models and to final lead deposi-
tion in bone in both mouse and man. - Environ Health Perspect 102(Suppl 3):215-219 (1994)
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Introduction
Exposure to environmental lead may affect
numerous organ systems, including the
renal, reticuloendothelial, reproductive, and
nervous systems. Ofparticular importance,
exposure to low levels oflead in utero or in
early childhood may lead to irreversible
central nervous system damage (1-8).
Although the reduced use ofleaded gasoline,
widespread detection of lead-based paint
poisoning of children, and control of lead
exposure in the workplace have combined
to substantially reduce the incidence of
acute lead poisoning in the United States,
exposure to low doses of lead is still quite
common. The Second National Health
and Nutrition Examination Survey
(NHANES-II) found that 1.5 million
preschool children had blood lead levels of
25 pg/dl and above, indicating significant
lead absorption.
The homooctameric zinc metalloen-
zyme, 6-aminolevulinate dehydratase (por-
phobilinogen synthase, ALAD, EC 4.2.1.24),
is the second enzyme in the heme biosyn-
thetic pathway. ALAD is expressed in all
This paper was presented at the Second International
Meeting on Mechanisms of Metal Toxicity and
Carcinogenicity held 10-17 January 1993 in Madonna
di Campiglio, Italy.
This research was supported by grant ES05046
from the National Institutes of Health.
Address correspondence to Dr. James G.
Wetmur, Department of Microbiology Box 1124,
Mount Sinai School of Medicine, New York, NY
tissues, but occurs at elevated levels in liver,
which has the added burden ofcytochrome
P450 synthesis, and in the highest levels in
erythrocytes and their precursors. ALAD is
stoichiometrically inhibited by lead (9-11),
with lead replacing zinc. Erythrocyte ALAD
inhibition has been used as a routine lead-
poisoning test in many clinical chemistry
laboratories.
Lead inactivation of ALAD has been
implicated in the pathogenesis of lead poi-
soning (12,13). The substrate ofALAD, 6-
aminolevulinate (ALA), which accumulates
in lead poisoning, has been shown to be
capable of acting as a neuropathogenic
agent (11,14-19). In fact, the clinical fea-
tures ofacute lead poisoning closely resem-
ble those of the acute attacks in acute
intermittent porphyria (AIP), during which
ALA accumulates. AIP is a dominant por-
phyria due to half-normal levels of the
third enzyme in the heme biosynthesis
pathway. Furthermore, affected individuals
with the recessive ALAD-deficient por-
phyria manifest chronic neurologic mani-
festations (20-22). Finally, asymptomatic
heterozygotes for the latter porphyria
develop acute lead poisoning when exposed
to low levels oflead (23,24).
Three distinct charge isozymes, desig-
nated ALAD 1-1, 1-2, and 2-2 (25,26),
result from the expression of two common
1 2 alleles, designated ALAD and ALAD
with gene frequencies of 0.9 and 0.1,
respectively, in several Caucasian popula-
tions (25-28). The existence of this fre-
quent polymorphism in a gene whose
product was implicated in the pathogenesis
oflead toxicity suggested the potential for a
genetically determined differential suscepti-
bility. We determined the ALAD isozyme
types of 1278 blood samples from children
subjected to low-level environmental lead
exposure in New York City (28,29). The
blood lead level, measured by the New
York City Lead Screening Program, and
the ALAD isozyme phenotype were deter-
mined in a double-blind fashion. Blood-
lead levels and isozyme phenotypes were
also determined for a population of 202
lead workers in a factory in Germany (30).
Analysis of both populations (29) revealed
that individuals carrying the ALAD2 allele
were at significantly greater risk oflead poi-
soning (pcO.0001 and p<0.004, respec-
tively), with individuals carrying the
ALAD allele having about 10 pg/dl higher
levels of blood lead than similarly exposed
individuals who were homozygous for
ALAD1 allele. Human ALAD and ALAD
cDNAs have been cloned and sequenced in
our laboratory (31,32), and a simple poly-
merase chain reaction (PCR) test, based on
different cleavage patterns ofthe two alleles
by MspI, has been developed for genotyp-
ing ALAD alleles of individuals in lead-
exposed populations (32). The present
status ofhuman studies ofthe contribution
of ALAD genotype to lead poisoning is
detailed below in the Results and Discussion
section. Ofspecial interest will be not only
the acute measure of erythrocyte lead but
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also the chronic measures of dentine or
bone lead.
The results reported above are consis-
tent with the testable hypothesis that the
ALAD2 subunit binds lead more effec-
tively, with similarly exposed ALAD2 het-
erozygotes and homozygotes having higher
blood lead concentrations and possibly
higher lead bodyburden thanALAD1 homo-
zygotes. We have developed an expression
system that allows production of large
quantities of human ALAD 1-1 and
ALAD 2-2 in Escherichia coli (Kaya AH
and Desnick RJ, unpublished results). The
present status ofbiochemical studies ofthe
contribution of these ALAD isozymes to
lead poisoning is detailed in the Results
and Discussion section. Ofparticular inter-
est will be the competition between lead
and zinc for binding to the isozymes.
The human genomic sequence contain-
ing AIAD has been determined (15,913
bp, accession number X64467) in both ori-
entations (33). The gene encodes 13 exons:
11 coding exons-exons 2 to 12-and 2
alternative noncoding exons-1A and 1B.
The promoter with exon IA was found to
function in all cells, while the promotor of
exon 1B functions exclusively in erythroid
cells. The Results and Discussion section
proposes mouse model experiments oflead
tissue distribution, based either on pub-
lished data showing variation in murine
ALAD gene dose in various mouse strains
(34) or on production of transgenic mice
carrying either ALAD1 or ALAD2 human
minigenes with promoters for either exon
IA or lB. Of special interest will be the
acute measure of erythrocyte lead, the
chronic measure of bone lead, and the
pathophysiologically important distribu-
tion oflead into brain.
Materials and Methods
Human Studies
Populations. To date only two populations
have been studied (double-blind) for blood
lead and ALAD phenotype (29). One
group consisted of 202 male workers who
were exposed to different amounts of lead
for different periods of time in a German
factory. The other group consisted of 1278
children from lower socioeconomic neigh-
borhoods in New York City; at least 27
and 20% were Black and Hispanic, respec-
tively. They had initially been screened for
possible lead poisoning by the New York
City Department of Health and found to
have elevated free erythrocyte protopor-
phyrin (FEP) levels.
Additional collaborations have been
established to study ALAD genotypes by
PCR and MspI cleavage analysis in popula-
tions in which a chronic measure of lead
exposure is available. H Hu, D Bellinger
(Harvard), H Needham (Pittsburgh):
chronic measure, dentine ofdeciduous teeth.
B Fowler, E Silbergeld (University of
Maryland): acute measure, blood lead;
chronic measure, bone lead. DR Chettle
(McMaster), L Cerhardsson, S Skerfving
(Lund), V Englyst (Boliden Metall AB):
acute measure, blood lead history; chronic
measure, bone lead. A Todd and P
Landrigan (Mount Sinai, NewYork): acute
measure, blood lead; chronic measure,
bone lead.
PCR ALAD genotyping by PCR is car-
ried out as previouslydescribed (32).
ALAD 1-1 andALAD 2-2Biochemistry
Expression Vectors. ALAD' andALAD2
cDNAs were ligated into a pUC19 vector
with a linker such that the inducible-
galactosidase promoter encoded a
cocistronic message encoding a short
polypeptide followed by the complete
human ALAD polypeptide (35). The con-
struct contained the sequence AAGCTTG-
GAGGAATTCTAACGCATG from the
pUC19 HindIII (AAGCTT) site to the
ALAD initiation codon (ATG), with TAA
being the terminator for the short polypep-
tide and AGGAA being a ribosome bind-
ing site. The vectors were cloned in E. coli
LC137, a lon- and htp- strain, and the
inserts were completely sequenced.
Recombinant Human ALAD 1-1 and
ALAD 2-2 Isozymes. Authentic, soluble,
and biologically active human ALAD 1-1
and ALAD 2-2 were synthesized. The
ALAD enzymatic activity was 0.7 U/mg
protein, over 1000 times that found in
human erythrocytes (0.45 mU/mg pro-
tein). The recombinant protein was identi-
cal to human erythrocyte protein by sedi-
mentation velocity, polyacrylamide gel
electrophoresis mobility, and Western blot-
ting (Kaya AH and Desnick RJ, unpub-
lished results). Purification ofALAD 1-1
and ALAD 2-2 follows the method of
Anderson and Desnick (36).
AnimalModelStudies
The 15,913 base pairs of human genomic
sequence containing ALAD1 were deter-
mined in both orientations (HSALADG,
accession number X64467 (33). The
analysis ofthe genome structure ofhuman
ALAD, necessary for constructing transgenic
mice expressing human ALAD, is illus-
trated in Figure 1.
Results and Discussion
HumanlStudies
The results of the two completed studies
demonstrating a relationship between
blood lead levels and ALAD phenotype
(29) are summarized in Table 1. In the 40
to 60 percentile group for blood lead in
each phenotype group, individuals with the
ALAD allele (phenotypes ALAD 1-2 and
ALAD 2-2) have of the order of 10 pg/dl
greater blood lead than similarly exposed
individuals homozygous for the ALAD1
allele (phenotype ALAD 1-1). The German
lead workers (FRG) showed the expected
ALAD2 gene frequency of about 0.1 for a
Caucasian population. The children from
New York City showed an ALAD2 allele
frequency of 0.06, consistent with inclu-
sion of approximately 30% of children of
African ancestry. No ALAD2 alleles were
detected in one African population (27).
The results were not changed in a reanalysis
excluding these children.
Table 1. Summary ofstatistics onthecorrelation ofALAD phenotype and blood lead.
Phenotype
ALAD 1-1 ALAD 1-2andALAD 2-2
Population Percentile Blood lead, pg/dl Blood lead, pg/dl
USA
Numberanalyzed 1136 142
40 12 20
50 15 26
60 18 32
Mean±SEM 19.5±0.3 27.1 ±1.3
FRG
Numberanalyzed 160 42
40 31 41
50 35 44
60 40 53
Mean ± SEM 38.4± 1.3 47.0 ± 2.8
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Figure 1. ALAD gene structure. Numbered exons are shown as large blocks. Promoter regions for noncoding exons 1A
and 1B are indicated.
The FRG population was unselected,
consisting of all participating lead workers
at a factory site. The USA population con-
sisted of children whose FEP levels on ini-
tial screening suggested the possibility of
lead poisoning. FEP levels are known to be
affected by other variables, including iron
status (36). Although the identical depen-
dence ofblood lead level on ALAD isozyme
phenotype for both populations argues
against any bias introduced by the FEP
prescreening ofthe USA population, addi-
tional population studies of ALAD geno-
type (and hence phenotype) and blood lead
are needed to prove the ALAD2 to be a
lead susceptibility allele. Blood lead and
ALAD genotype studies are in planning or
in progress in populations 2 to 4 (Materials
and Methods), and we welcome additional
collaborative arrangements.
Blood lead is an acute measure of lead
exposure. For example, there was insignifi-
cant correlation between time on the job
and blood-lead level in the FRG popula-
tion. If we accept the hypothesis that the
ALAD 2 polypeptide binds lead tighter
than the ALAD 1 polypeptide, the effect of
this enhanced binding oflead on the even-
tual tissue distribution of lead cannot be
predicted. In one scenario, ALAD 2, which
is present at much higher concentrations in
blood than in other tissues, could compete
with lead binding proteins in brain or
other organs and reduce pathology. On the
other hand, increased inhibition of heme
synthesis in tissues with low levels ofALAD
could increase pathology. An important
contribution to understanding the lead dis-
tribution problem would be to correlate
instantaneous blood lead levels and lead
body burden.
Integrated measures of lead exposure
indude lead in dentine of deciduous teeth
ofchildren and bone lead in both children
and adults. Measurements ofALAD geno-
type together with integrated measures of
lead exposure are in planning or in progress
in populations 1 to 4 (Materials and
Methods). The populations are listed in
increasing order of numbers of subjects.
Because of the low frequency ofALAD2
even in Caucasian populations, the popula-
tions oflead-exposed individuals on whom
integrated measures are performed must be
quite large to lead to highly informative
data; not even the largest of the popula-
tions identified to date is ideal. Once again,
we invite collaborative arrangements.
ALAD 1-1 andALAD 2-2 Biochemistry
The argument that erythrocyte ALAD
binds a substantial fraction of the blood
lead is outlined in Table 2. A unit (U) of
ALAD is defined as the quantity of enzyme
producing 1 nmole porphobilinogen
(PBG) per hour at 370C. The calculation
includes the ALAD activity in human ery-
throcyte lysate (38) of approximately 4.7
U/mg protein (mostly hemoglobin) and
the turnover number of 11 mole/min/mole
ALAD subunit (36). The conclusion is that
at least 10 pg/dl lead is bound to ALAD at
25 jig/dl total blood lead. This minimum
estimate is based on ALAD enzymatic
activity, which decreases throughout the
120-daylife-span oferythrocytes. Additional
lead could be bound to inactive ALAD.
Thus the difference in observed blood lead
values for individuals with different ALAD
phenotype could be explained by the
hypothesis thatALAD 2 subunits bind lead
more avidly than ALAD 1 subunits.
Further support for this hypothesis
could be obtained by comparison of the
lead binding properties of the purified
ALAD 1-1 and 2-2 proteins. To accom-
plish this objective, milligram quantities of
the isozymes ALAD 1-1 and ALAD 2-2
would be needed, and the only practical
source would be recombinant enzymes.
Previous studies ofthe activities ofthe ery-
throcyte ALAD 1-1 orALAD 2-2 isozymes
have failed to detect a difference [(25,30),
Ostasiewicz and Desnick, unpublished
results], but these studies were carried out
either with unpurified or with limited
quantities of purified ALAD 2-2 isozyme.
As described in Materials and Methods,
our efforts to date have been directed
toward developing an efficient systems for
expression of recombinant human ALAD
1-1 and ALAD 2-2 in E. coli. Now that
these recombinant human ALAD isozymes
are in hand, we are undertaking a systematic
examination of the competitive binding of
lead and zinc and the effect oflead binding
on ALAD enzymatic activity.
Animal Model Studies
To understand the physiologic conse-
quences of the increased blood lead
observed in individuals with the ALAD2
allele, we must understand the effect of
ALAD isozyme phenotype on the distribu-
tion oflead to other organs, induding kid-
ney, where specific metal-binding proteins
mediate the effect of lead on ALAD,
bone-the ultimate repository of much of
the lead-and especially brain. Mice are
especially sensitive to the effects of lead,
and lead binding in various organ systems
is readily determined. Furthermore, unin-
hibited erythrocyte ALAD activity is pro-
portional to gene dose in commercially
available mouse strains carrying one
(C57BL/6), two (C58), or three (DBA/2)
copies ofthe murine ALAD gene per hap-
loid genome (33). Thus we are investigat-
ing these mice to establish the effect of
ALAD concentration, especially in serum,
on the pharmacokinetics oflead tissue dis-
tribution. These studies will be the basis for
measurement and analysis in the more
important animal model system based on
expression ofhuman ALAD alleles in trans-
genic mice.
Table Lead binding to erythrocyte ALAD and blood
lead.
ALAD
Erythrocyte ALADactivity =4.7 nmole PBG/hr/mg lysate
protein(38)
Reference: Whole blood contains 155 mg hemoglo-
bin/ml
Thus,erythrocyteALADactivity2 12 nmole
PBG/min/ml whole blood
Tumovernumber = 11 nmole PBG/min/nmole ALAD
subunit(35)
ALAD Subunits 1 nmole/mlwhole blood
Lead
1 nmole/ml = 21 pg Pb/dll
ALAD inhibition by lead
Inhibition iswithoutthreshold
Approximately50% inhibited at25 pg Pb/dl
Conclusion
> 10 pg Pb/dl bound toALAD at25pg/dl blood lead
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As described in Materials and
Methods, our efforts to date have been
directed toward analysis of the human
ALAD gene with particular emphasis on
the promoter regions. The structure ofthe
human ALAD gene is shown in Figure 1.
Expression analysis of the two promoters
reveals that in both cases a DNA sequence
of less than 400 base pairs produces as
much product as longer constructs and
exhibits tissue specificity. Thus, four
minigenes are being constructed contain-
ing either exons 2 tol2 of ALAD1 or
ALAD and either exon 1A or exon lB
with their corresponding promoters. We
propose to construct transgenic mice
expressing similar numbers of copies of
either the human ALAD or ALAD2
allele. The analysis of lead-exposed ani-
mals will be directed toward the study of
the acute measure oferythrocyte lead, the
chronic measure of bone lead, and the
pathophysiologically important distribu-
tion of lead into brain. In summary, we
are taking advantage ofthe tools ofmolec-
ular biology to study the ecogenetics of
lead poisoning. Our integrated tripartite
approach is to study ALAD allele fre-
quency in lead-exposed individuals by
PCR, ALAD isozyme biochemistry with
recombinant proteins, and the effect of
human ALAD alleles on lead pharmacoki-
netics in transgenic mice.
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